Literature DB >> 3397535

Evidence for a C4b binding site on the C2b domain of C2.

T J Oglesby1, M A Accavitti, J E Volanakis.   

Abstract

We raised murine mAb against human C protein C2. The representative mAb 3A3.3 (IgG1 kappa) recognized an epitope on the C2b domain of C2, as determined by binding and inhibition of binding radioassays. The hemolytic activity of purified human C2 and of C2 in normal human serum was inhibited by the mAb. The rate of decay of the C3-convertase at 30 degrees C was not affected by the mAb. C2 binding to EAC4b was inhibited by intact IgG and the Fab fragment of the mAb; 50% inhibition required 1 microgram/ml of either. The data suggest the presence of a C4b-binding site on the C2b domain of C2 and that the mAb recognizes an epitope at, or adjacent to, this site. The C2b portion of the C2 molecule may be important in assembly of the classical pathway C3-convertase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3397535

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Interallelic complementation at the Drosophila melanogaster gastrulation defective locus defines discrete functional domains of the protein.

Authors:  G Ponomareff; H Giordano; Y DeLotto; R DeLotto
Journal:  Genetics       Date:  2001-10       Impact factor: 4.562

2.  The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.

Authors:  Vengadesan Krishnan; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

3.  Effect of sodium chloride concentration on fluid-phase assembly and stability of the C3 convertase of the classical pathway of the complement system.

Authors:  S Maeda; S Nagasawa
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

4.  The principal site of glycation of human complement factor B.

Authors:  M A Niemann; A S Bhown; E J Miller
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

5.  Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.

Authors:  Kwok-Min Hui; George L Orriss; Tilman Schirmer; Bergljót Magnadóttir; Jürg A Schifferli; Jameel M Inal
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

6.  Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues.

Authors:  Kwang-Seok Oh; Mee-Hyang Kweon; Ki-Hyeong Rhee; Keyong Ho Lee; Ha-Chin Sung
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.